What coverage agrees on
All reports agree that Qdenga is India’s first approved dengue vaccine and that a Takeda-Dr Reddy’s deal sets up a 2027 launch. They also agree that the initial rollout is tied to the private market.
Dengue Vaccine · India
India’s First Dengue Vaccine Set for 2027 Launch
CATCH ME UP
Takeda and Dr Reddy’s Laboratories have signed a distribution agreement for Qdenga in India.
The vaccine was granted marketing authorisation by the Central Drugs Standard Control Organisation in July 2026 for people aged 4 to 60 years.
Dr Reddy’s will handle private-market promotion and distribution.
Takeda retains public market rights and overall brand ownership.
Why it mattersIndia’s first approved dengue vaccine could expand prevention in a country where dengue cases strain hospitals each year, affecting rollout timing, supply, and access.
More context
Pricing has not yet been decided, and dengue remains a significant public health challenge.
AGREEMENT VS DISAGREEMENT
What lines up. What splits.
A quick read on shared facts, changing details, and different emphasis.
What is changing or disputed
Pricing has not yet been decided, and the local regulatory process is still being completed. The timing and broader market reach could change as those steps finish.
HOW COVERAGE DIFFERS
Same story. Different emphasis.
Swipe through the perspectives. Labels describe coverage framing, not truth or quality.
Neutral4
The reporting is broadly factual and process-focused, describing approval, distribution rights, and the planned 2027 launch. It also notes that the vaccine is intended for people aged 4 to 60 years. One report says dengue remains a significant public health challenge. private market is the main rollout channel described.
Distinctive emphasis — reported claim, not independently verified.Sources: The Hindu
STORY TIMELINEHow the coverage developed
The latest eight dated reports, from earliest to newest.
How the coverage developed
FIRST-PARTY STATEMENTS
What the parties are saying
Attributed summaries from official party channels. These are claims, not independent reporting or fact checks.
GO DEEPER
Read the reporting
Scan each source take, then open the original article.
India to Launch First Approved Dengue Vaccine Qdenga in 2027
Quick source take
The Hindu reports that Takeda Pharmaceutical Company and Dr Reddy’s Laboratories have signed a distribution agreement to launch India’s first approved dengue vaccine, Qdenga, in the first half of 2027. The vaccine received marketing authorisation from the Central Drugs Standard Control Organisation in July 2026 for individuals aged 4 to 60 years. While public immunisation inclusion remains a long-term goal, Dr Reddy’s will exclusively promote and distribute the vaccine in the private market.
Dr Reddy’s to distribute Qdenga, India’s first dengue vaccine | India News
Quick source take
Hindustantimes.com reports that Hyderabad-based Dr Reddy’s Laboratories will distribute Takeda Pharmaceuticals' Qdenga vaccine across India’s private market for paediatric and adult vaccination starting in the first half of 2027. Company officials stated that pricing has not yet been decided as local regulatory processes are still being completed following the July marketing authorisation. The article highlights that dengue remains a significant public health challenge with all four serotypes co-circulating.
India to Launch Qdenga the First Approved Dengue Vaccine in 2027
Quick source take
The Hans India reports that Takeda Pharmaceutical Company and Dr Reddy’s Laboratories signed an agreement to distribute Qdenga, India’s first approved dengue vaccine, in the private market starting in the first half of 2027. The vaccine was approved by the Central Drugs Standard Control Organisation in July 2026 for individuals aged 4 to 60 years. Takeda will retain public market rights and overall brand ownership while Dr Reddy’s manages private market promotion and distribution.
India’s First Dengue Vaccine QDENGA to Launch in 2027 After Takeda-Dr Reddy’s Distribution Deal
Quick source take
The Sunday Guardian reports that India is set to launch its first approved dengue vaccine, Qdenga, in the first half of 2027 following a distribution deal between Takeda and Dr Reddy’s Laboratories. The vaccine, authorised by the CDSCO in July 2026 for individuals aged 4 to 60, will be distributed exclusively in the private market by Dr Reddy’s while Takeda retains public market rights. The article also notes clinical trial efficacy data and rising dengue cases in India.